Why the study?
Does antiarrhythmic treatment improve survival in patients with potentially lethal ventricular arrhythmias?
Does antiarrhythmic treatment improve survival in patients with potentially lethal ventricular arrhythmias?
This review highlights the intermediate risk of sudden death (10-38%) in patients with potentially lethal ventricular arrhythmias and structural heart disease, and discusses the role of antiarrhythmic therapy.
Antiarrhythmic effects on survival in potentially lethal ventricular arrhythmias remain uncertain; leaves open need for targeted randomized trials.
Patients with potentially lethal ventricular arrhythmias (VAs) represent a heterogenous group with frequent and high grade ventricular arrhythmias (including couplets and runs of nonsustained ventricular tachycardia), structural heart disease and decreased left ventricular function. This is a group at intermediate risk of sudden death, with risks varying from 10% to 38%. The electrical and mechanical risks of patients with potentially lethal VA is discussed in relation to their ability of promoting sudden death. The studies reviewing the impact of antiarrhythmic treatment on survival of patients with potentially lethal VA is discussed.
No takes yet. Share an insight, caveat, or question.
Kerin et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: